Imaging study for amyloidosis in heart and body
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are either a healthy volunteer, or you have a confirmed diagnosis of AL or ATTR amyloidosis that affects your heart
- You are not pregnant or breastfeeding, and you agree to use birth control during the study
- You have not had a nuclear medicine imaging study in the past 6 months
- You are not on dialysis, and you do not have severe claustrophobia or certain other medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent that helps doctors see amyloid buildup in the heart using a PET scan. It may help diagnose cardiac amyloidosis more accurately and guide treatment decisions.
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This study uses a hybrid PET/MRI scanner to take detailed images of the heart in people with amyloidosis. The goal is to see how well this scan shows the buildup of amyloid protein, which could help doctors better diagnose and manage the condition.
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
This study collects information from adults who have been diagnosed with, or are being checked for, ATTR amyloidosis (a condition where abnormal protein builds up in the body) using a heart PYP scan. Your participation may help doctors better understand how these scans relate to diagnosis and follow-up over time.
Hear when a new Systemic Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.